When Tracy Tomlinson was offered an experimental cancer treatment, she said yes almost straight away.

The 58-year-old from Chadderton, Oldham, became the first person to receive ZI-MA4-1 at The Christie hospital in Manchester as part of a clinical trial evaluating the treatment for several types of cancer.

The therapy will be tested on people with ovarian cancer, lung cancer, sarcomas, and head and neck cancer in a trial led by The Christie, with a site at the Royal Marsden in London.

Tomlinson said it was a “little bit scary” being the first person to have the treatment.

Many people in the early-stage study, which is primarily focused on safety, have few other options for survival.

Tomlinson has undergone surgery and several rounds of chemotherapy since she was diagnosed in 2020.

She said she was diagnosed as stage 3C, which means there were cancer growths spreading into the peritoneum of the body. She currently has a tumour between the liver and kidney, as well as small tumours elsewhere.

“It is a lot to live with and there’s been ups and downs – there’s been elation, there’s been disappointment, and bits in between,” Tomlinson said.

“But I try very, very hard to remain very positive. Every day that I wake up is a positive. You’ve got to have hope.”

The new therapy combines two methods in fighting cancer. It uses the body’s natural killer cells, specialist immune cells that destroy abnormal ones. It also uses engineered T-cell receptors on the cells to recognise and target tumours producing a protein called Mage-A4.

Mage-A4 is found in several types of cancer and experts believe it is an ideal target for attacking abnormal cells.

Unlike some personalised treatments, ZI-MA4-1 is designed as an “off-the-shelf” therapy that uses immune cells from donors. The treatment is manufactured in advance from donor cells rather than being individually tailored to each patient, with hundreds of doses produced from a single manufacturing batch.

Experts believe this could mean advanced cell therapies are available to more patients more quickly, and at a cheaper cost.

Last year, Tomlinson was referred to The Christie’s early phase clinical trials team and learned she was a suitable candidate for the Zima-101 clinical trial.

“I decided almost straight away that I was going to go for it,” she said.

She has had three infusions of the therapy, with the option of another one depending on what scans show.

“If it benefits me, absolutely fantastic,” she said. “But if it benefits other people in the future, that’s important too.

“I don’t want to have gone through everything I’ve gone through for nothing. I want to feel like I have made a difference.”

Tomlinson, a former civil service manager, said in her working life she was target-driven and set herself very high standards.

“But you can’t control cancer,” she said. “What I can control is how I look at it, how I deal with it, and trying to eat healthily and taking the positives in everything.

“And I’ve learned to appreciate the smallest of things that we take for granted – and the people around you and what they mean to you.

“Also, the beauty of outside and the trees and the colour of the trees and the birds singing.”

Prof Fiona Thistlethwaite, consultant medical oncologist at The Christie, said: “While this is an early-stage study primarily focused on safety, it represents an exciting step forward in efforts to develop new treatment options for people like Tracy with advanced solid tumours.”

She said it could “help shape future cancer treatments and ultimately improve outcomes for patients”.

Dr Jon Lim, consultant medical oncologist in advanced immunotherapy and cell therapy at The Christie, said the approach was “very exciting”.

“This is the first of its kind globally – where it’s taking donor immune cells, manipulating or engineering them, and putting them into the recipient,” he said.

“Tracy is essentially getting somebody else’s immune cells that have been engineered to ‘see’ her cancer.”

Namir Hassan, of Norwegian firm Zelluna, which makes ZI-MA4-1, said Tomlinson’s first dose was a “landmark moment”.

Only around 15 percent of women survive ovarian cancer for five years or more after they are diagnosed.

Read more from BBC News.